Investor Relations

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.

View all »   RSSRecent Releases

Jun 25, 2014
Merrimack Pharmaceuticals Presents Data From Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer

Jun 19, 2014
Merrimack Pharmaceuticals to Regain Worldwide Rights to Develop and Commercialize MM-121

Jun 17, 2014
Merrimack Pharmaceuticals Announces Oral Presentation of Additional Data Results in Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer

Jun 2, 2014
Merrimack Pharmaceuticals Presents Phase 1 Clinical Data Supporting Four Novel Antibody Therapeutic Programs at the 2014 ASCO Annual Meeting

Stock Quote (NASDAQ: MACK)

Price:
5.71

Change:
- 0.19

Day High:
5.90

Day Low:
5.70

Volume:
752,800

4:00 PM ET on Jul 25, 2014
Delayed ~20 min. By eSignal.

Shareholder Tools